What’s the current market cap for Medtronic stock?

Medtronic (MDT) has a market cap of $103bn as of June 24, 2026.

What is the P/E ratio for Medtronic stock?

The price to earnings (P/E) ratio for Medtronic (MDT) stock is 21.62 as of June 24, 2026.

Does Medtronic stock pay dividends?

Yes, the Medtronic (MDT) stock pays dividends to shareholders. As of June 24, 2026, the dividend rate is $2.84 and the yield is 3.52%. Medtronic has a payout ratio of 75.8% on a trailing twelve-month basis.

When is the next Medtronic dividend payment date?

The next Medtronic (MDT) dividend payment is scheduled for July 17, 2026.

What is the beta indicator for Medtronic?

Medtronic (MDT) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Medtronic stock | $MDT Share Price

About Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Ticker

$MDT

Sector

Health

Primary listing

NYSE

Employees

95,000

Headquarters

Galway, Ireland

Website

www.medtronic.com

Medtronic Metrics

BasicAdvanced

$103bn

21.62

$3.73

0.60

$2.84

3.52%

What the Analysts think about Medtronic

Analyst ratings (Buy, Hold, Sell) for Medtronic stock.

Bulls say / Bears say

Worldwide cardiac ablation heart device sales rose 80% in the quarter, driven by robust demand for pulsed field ablation (PFA) technology, reinforcing Medtronic’s leadership in heart device innovation. (Reuters)

Medtronic’s planned $650 million acquisition of SPR Therapeutics, announced May 20, 2026, expands its chronic pain portfolio and is expected to be immediately accretive to adjusted earnings per share. (Reuters)

The board approved a quarterly dividend increase to $0.72 per share, marking its 49th consecutive annual dividend hike and demonstrating Medtronic’s strong commitment to shareholder returns. (Investing.com)

Medtronic expects an incremental $300 million hit from U.S. tariffs in fiscal 2027, up from around $185 million in fiscal 2026, which is projected to pressure gross margins in the first half of the year. (Reuters)

Despite robust device sales, the company maintained its full-year adjusted profit forecast, with the finance chief warning that extra tax costs will erode some profit upside and that pulsed field ablation growth, while up 80%, fell short of buy-side expectations. (Reuters)

Medtronic Cardiac Surgery issued an urgent Class II recall of its DLP retrograde cannula on April 21, 2026 due to risk of device failure, underscoring ongoing quality control and regulatory compliance challenges. (FDA)

Data summarised monthly by Lightyear AI. Last updated on 15 Jun 2026.

Medtronic Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Medtronic Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Medtronic News

AllArticlesVideos

This Undervalued Medical-Devices Stock Is Poised for a Rebound

Barrons·6 days ago

As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play

Investopedia·2 weeks ago

Wall Street May Be Mispricing Medtronic, Analyst Says

Benzinga·3 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.